Rationale and Design of the Phase 3 KEYLYNK-013 Study of Pembrolizumab With Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Limited-Stage Small-Cell Lung Cancer

Authors:

Abstract
No abstract available
Funding Information
  • Merck & Co Inc
  • Merck Sharp and Dohme United Kingdom
  • National Institutes of Health
  • National Cancer Institute (P30 CA008748)

This publication has 16 references indexed in Scilit: